Prognostic impact of sodium-glucose cotransporter 2 inhibitor on patients with heart failure
BIE Bi-ke
ZHANG Yao
Abstract：Objective To assess the effect of sodium-glucose cotransporter 2 inhibitor(SGLT2i)on outcomes in patients with mild-reduced ejection fraction heart failure(HFmrEF)and ejection fraction-preserved heart failure(HFpEF).Methods The patients with HFmrEF and HFpEF diagnosed in the Department of Cardiology,The Second Affiliated Hospital of Harbin Medical University from March 2021 to June 2023 were grouped into the observation group(n=208)and the control group(n=692)according to whether they had taken SGLT2i orally at the time of discharge.The clinical data of the selected patients were collected through the electronic medical record database system.The main outcome measures were cardiacvascular death and rehospitalization with heart failure.Results Univariate analysis showed that,compared with patients in the HFmrEF control group,HFmrEF patients who used SGLT2i had a statistically significant potential benefit in hospitalization rate due to heart failure(P=0.013),but no significant potential benefit in mortality due to cardiovascular disease(P=0.409).Compared with patients in the HFpEF control group,SGLT2i HFpEF patients had a statistically significant potential benefit in hospitalization rate due to heart failure(P=0.012),but no significant potential benefit in cardiovascular mortality(P=0.150).Multivariate analysis showed that patients in the HFmrEF observation group had a 65.1％lower risk of rehospitalization due to heart failure than those in the HFmrEF control group(HR=0.349,95％CI 0.130-0.935,P=0.036).Compared with patients in the HFpEF control group,patients in the HFpEF observation group had a 58.4％lower risk of re-hospitalization due to heart failure(HR=0.416,95％CI 0.200-0.867,P=0.019)and a 76％lower risk of death due to cardiovascular disease(HR=0.240,95％CI 0.058-0.991,P=0.048).Conclusions SGLT2i reduces the risk of cardiac death and heart failure rehospitalization in patients with HFmrEF and HFpEF,and improves the patient outcomes.
Keywords：Sodium-glucose cotransporter 2 inhibitorHeart failure with reduced ejection fractionHeart failure with preserved ejection fractionPrognosis
Publication Date：2024-11-10
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：8( 1013-1020 )